Cat. No. 2694
Chemical Name: 9-Hydroxy-4-phenyl-pyrrolo[3,4-c]ca
Biological ActivitySelective inhibitor of checkpoint kinases Chk1 and Wee1 (IC50 values are 47 and 97 nM respectively). Displays selectivity over a range of other protein kinases; IC50 values are 3.4, 3.75, > 5, > 50, > 50 and > 50 μM for PKC, CDK4, other CDKs, c-Src, PDGFR and FGFR respectively.
Licensing InformationSold for research purposes under agreement from Pfizer Inc.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Palmer et al (2006) 4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenylring substitutions. J.Med.Chem. 49 4896. PMID: 16884302.
Squire et al (2005) Structure and inhibition of the human cell cycle checkpoint kinase, Wee1A kinase: an atypical tyrosine kinase with a key role in CDK1 regulation. Structure 13 541. PMID: 15837193.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for PD 407824 include:
Kishikawa et al (2015) Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine. Oncotarget 6 8339. PMID: 25826076.
Pouliot et al (2012) Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res 72 5945. PMID: 22942255.
Do you know of a great paper that uses PD 407824 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: PD 407824, supplier, Selective, inhibitors, inhibits, Chk1, Wee1, Checkpoint, Control, Kinases, PD407824, Pfizer, Tocris Bioscience, Checkpoint Kinase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent group I PAK inhibitorMRT 68921 dihydrochloride
Potent ULK inhibitor; inhibits autophagyAM 2394
Potent glucokinase activator; orally bioavailableeCF 309
Potent mTOR inhibitorPF 3758309 dihydrochloride
Potent PAK4 inhibitor; orally availableAZ Dyrk1B 33
Potent and selective Dyrk1B kinase inhibitorPF 06409577
Potent and selective allosteric activator of AMPKPerifosine
PKB/Akt inhibitor; also modulates Kv2.1 currentRAF 265
Raf kinase and VEGFR-2 inhibitorCZC 25146
Potent LRRK2 inhibitorRo 3280
Potent and selective PLK1 inhibitorRMM 46
MSK/RSK family kinase inhibitorLTURM 34
Potent DNA-PK inhibitorMLi-2
Potent and selective LRRK2 inhibitorLTURM 36
PI 3-kinase δ inhibitorPI 3065
Potent and selective PI 3-kinase p110δ inhibitorAZ PFKFB3 67
Potent and selective PFKFB3 inhibitorSTOCK2S 26016
Lysine deficient protein kinase (WNK) signaling inhibitorrac-CCT 250863
Potent Nek2 inhibitorRoscovitine
Potent, selective cyclin-dependent kinase inhibitor
April 1 - 5, 2017
Washington, D.C., USA